Vista Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023
For the nine months, sales was INR 71.55 million. Revenue was INR 73.91 million. Net loss was INR 46.03 million compared to INR 17.88 million a year ago. Basic loss per share from continuing operations was INR 1.05 compared to INR 0.54 a year ago. Diluted loss per share from continuing operations was INR 0.75 compared to INR 0.31 a year ago. Basic loss per share was INR 1.05 compared to INR 0.54 a year ago. Diluted loss per share was INR 0.75 compared to INR 0.31 a year ago.